Preprints – versions of manuscripts posted on public servers before formal peer review – are shaking up the world of bioscience publishing, and they have been crucial during the COVID-19 pandemic for sharing results rapidly and widely. However, despite their benefits, the use of preprint servers for sharing pharma-funded research remains low.
To address this issue, we have created a new educational resource that explores how and why preprint servers are a valuable tool for disseminating pharma research. The resource covers:
- the different types of preprint servers available
- the benefits of sharing pharma research before peer review
- the potential risks of sharing pharma research through preprint servers and how to mitigate them.